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New Technologies in Clinical Microbiology
Donna M. Wolk1* and W. Michael Dunne, Jr.2
University of Arizona, College of Medicine, BIO5 Institute, Tucson, Arizona 85724-5059,1 and Department of
Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri2
Rapid identification of microorganisms in the clinical microbiology laboratory can be of great value for
selection of optimal patient management strategies for infections caused by bacteria, viruses, fungi, mycobac-
teria, and parasites. Rapid identification of microorganisms in clinical samples enables expedient de-escala-
tion from broad-spectrum agents to targeted antimicrobial therapy. The switch to tailored therapy minimizes
risks of antibiotics, namely, disruption of normal flora, toxic side effects, and selective pressure. There is a
critical need for new technologies in clinical microbiology, particularly for bloodstream infections, in which
associated mortality is among the highest of all infections. Just as importantly, there is a need for the clinical
laboratory community to embrace the practices of evidence-based interventional laboratory medicine and
collaborate in translational research projects to establish the clinical utility, cost benefit, and impact of new
technologies.
The topic “new technologies” described here was part of a
group session entitled Clinical Microbiology in the Year 2015,
part of the 2011 Camp Clin Micro meeting held in Houston,
TX. The discussion focused on new and emerging laboratory
methods, specifically those related to identification of blood-
stream infections (BSIs), which are among the most critical of
any infections characterized in clinical microbiology.
Rapid identification of BSIs and the associated condition
known as sepsis syndrome are of particular importance be-
cause of associated morbidity and mortality. Sepsis, a common
sequela of BSIs, ranks among the top 10 causes of death in the
United States, where over 600 patients die each day (11, 12,
17). Furthermore, the incidence of BSI is expected to increase
by as much 10% annually in the coming years (1, 7, 8, 12, 17),
adding an enormous social and economic burden to U.S.
health care systems. Estimated costs exceed $17 billion dollars
per year (1, 7, 12).
According to the literature, the risk of death from septic
shock increases by over 7% with every hour that passes from
the onset of shock until the start of targeted therapy (34). A
number of other studies confirm the urgency of rapid iden-
tification of pathogens and its benefit to survival and costs
and the effective targeting of antimicrobial therapy (13, 25,
29, 33, 45).
Unfortunately, when laboratory methods rely solely on cul-
tivation of pathogens and traditional phenotypic methods of
pathogen characterization, physicians are forced to deduce the
presence of BSI based on clinical symptoms, which are often
nonspecific. Subsequently, antibiotic therapy is initiated based
on clinical and epidemiologic profiles (28) rather than on lab-
oratory evidence. Typically, within 1 to 3 days a microscopic
Gram stain category (Gram-positive bacteria, Gram-negative
bacteria, or fungi) provides physicians with a general direction
for antibiotic therapy. Definitive results that eliminate the
need for broad-spectrum therapy and enable de-escalation and
the tailoring of treatment to the most effective antibiotic reg-
imen often require more than 3 to 5 days. This gap has been
implicated as one reason for high mortality and the emergence
of drug-resistant microbes. The gap is even more prolonged for
organisms that are fastidious, slow growing, noncultivable, or
present as part of polymicrobial infections. Rapid de-escala-
tion to narrow-spectrum antimicrobial therapy is a key aim of
Surviving Sepsis Campaign guidelines created to reduce mor-
tality for sepsis and BSI (13, 29).
There is evidence that laboratory interventions that decrease
reporting time can be effective. Efforts to demonstrate the
benefit of rapid reporting of Gram stain results showed that
mortality decreased by 17% when Gram stain reports from
positive blood culture (BC) bottles were reported in less than
1 h from the instrument flag (4). Furthermore, work performed
by Doern et al. and Barenfanger et al. indicated that more
timely interpretation of data from antimicrobial susceptibility
testing (AST) can greatly impact patient outcomes (3, 15).
Despite the evidence showing that the rapid administration
of an effective antibiotic saves lives (13, 25, 29, 33, 45), tools in
clinical microbiology are primarily based on techniques that
evolved 30 to 40 years ago (18). There is an urgent need for
new technologies in microbiology to circumvent the issue of lag
time for reports from positive blood cultures and other cul-
tures.
Several technological advances using simple molecular
methods have become available in recent years and show po-
tential for cost benefit, specifically, peptide nucleic acid fluo-
rescent in situ hybridization (PNA-FISH) (21–24, 36, 40) and
targeted real-time PCR such as GeneXpert assays (5, 48).
PNA-FISH has been the technology most studied in terms of
the collaboration between pharmacy and medical intervention.
In 2006, Forrest et al. demonstrated that PNA-FISH could be
used to distinguish Staphylococcus aureus species from coagu-
lase-negative staphylococci (CoNS). This study surveyed the
impact on hospital costs, length of patient stay, and the use of
vancomycin. The implementation of this strategy was linked to
lower hospital costs (approximately $4,000 lower per patient),
decreased length of stay (2 days), and decreased use of van-
comycin (23). A follow-up study performed by Ly et al. (36)
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showed a similar reduction in length of stay (2 days) for routine
patients and a 7-day reduction for patients in intensive care
units (ICUs). The median cost reduction was $19,441 per pa-
tient. Most dramatic was the overall reduction in mortality
rate, which fell from 16.8% to 7.9%. Specifically in the ICU,
mortality was reduced from 47.8% to 9.5%. These benefits
emphasize the positive impact of rapid molecular testing in the
clinical laboratory. More evidence-based studies to character-
ize the utility of these and other PNA-FISH assays, such as
those for Candida species and Gram-negative rods, are war-
ranted.
In addition to PNA-FISH, a real-time PCR method is avail-
able for rapid testing of blood culture bottles. The benefit of
the Xpert MRSA/SA BC assay (for methicillin-resistant S.
aureus/S. aureus blood culture test) was assessed, and clinical
improvements, such as decreased length of stay and health care
costs, were documented in a set of 156 patients. In this study,
the mean time to switch from empirical vancomycin to cefaz-
olin or nafcillin in patients with methicillin-susceptible S. au-
reus bacteremia was 1.7 days shorter post-PCR (P  0.002). In
the post-PCR methicillin-susceptible and methicillin-resistant
S. aureus groups, the mean length of stay was 6.2 days shorter
(P  0.07), and the mean hospital costs were $21,387 less (P 
0.02).
Both PNA-FISH and real-time PCR methods are easy to
perform and can be readily adapted into the laboratory work
flow. These technologies can complement existing practices
such as rapid reporting of Gram stain results (3) for better
patient management. Both PNA-FISH and real-time PCR
hold individual merit, but limitations exist because of the lim-
ited menu of test organisms. In addition, each method requires
time to gather supplemental information, such as Gram stain,
to permit cost-effective assay/kit selection. The technologies
would benefit from the addition of a multiple-target approach.
Multiplex and broad-range molecular diagnostics hold the
promise of decreased time to results and increased sensitivity
compared to growth-based blood culture systems but have not
yet been fully exploited. To date, there are no existing clinical
laboratory methods with equivalent analytical sensitivity com-
parable to that of routine blood cultures. Methods that allow
for the simultaneous detection of multiple targets could pro-
vide a huge advantage for molecular-based methods by pro-
viding identification and resistance information concurrently.
These methods are currently accurate for a small subset of
microorganisms but show promise in terms of clinical and fiscal
benefits. Broad-range strategies that aim to characterize bac-
teria and yeast and other microbes and that do not require
prior knowledge of the genetic target are considered most
desirable.
There are thousands of pathogens known to cause disease in
humans, and standard PCR assays have been developed to
detect the most commonly occurring pathogens. To meet the
analytical needs of broad-range microbial identification, two
additional strategies are currently in development for clinical
laboratories: pyrosequencing and multitarget PCRs.
Pyrosequencing methods, while accurate (30, 42), make
large demands on the technician’s time to assess and compare
sequences. The cost of the instrument is relatively high, but
utility has been documented (31). The technology’s use has
been mostly limited to identification of microbial isolates and
research for the identification of pathogens in blood culture
bottles.
Real-time PCR methods are undergoing evaluation, but
concordance with routine methods needs improvement. The
Roche Molecular System LightCycler SeptiFast (47) is avail-
able and has been evaluated for rapid detection of specific
organisms in blood culture bottles. The performance of Septi-
Fast for positive blood cultures is evolving. The concordance of
SeptiFast and BC for both positive and negative samples was
only 86.0% (46), and to date no clinical utility studies have
been published.
Recently, SepsiTest from Molzym was evaluated. The SepsiTest
uses a universal PCR from the 16S rRNA gene, with subse-
quent identification of bacteria from positive samples by se-
quence analysis of amplicons. Compared to blood culture
(BC), the diagnostic sensitivity and specificity of the PCR were
87.0 and 85.8%, respectively (n  342) (46).
Promising new broad-based techniques have merit, based on
their ability to identify organisms difficult to culture or newly
emerging strains, as well as their capacity to track disease
transmission. Two techniques revolve around mass spectrom-
etry (MS) technology: PCR combined with electrospray ion-
ization-mass spectrometry (PCR/ESI-MS) and matrix-assisted
laser desorption ionization–time of flight mass spectrometry
(MALDI-TOF MS).
Both mass spectrometry methods leverage the high sensitiv-
ity of mass spectrometry with links to large microbial data-
bases, which enable users to obtain species-specific spectra that
can be used to reproducibly identify microorganisms. Use of
mass spectrometry methods is challenged by the high costs of
instruments, yet there is potential for these technologies to
supplant the foundation of clinical microbiology, replacing
most biochemical testing as we know it. Both of these ap-
proaches require the purchase of a dedicated mass spectrom-
eter and software package, with PCR/ESI-MS approximately
two to three times the cost of MALDI-TOF MS. Expected
differences occur for the day-to-day cost of consumables, which
varies between high-cost PCR/ESI-MS and lower-cost
MALDI-TOF MS. PCR/ESI-MS requires DNA extraction re-
agents used for PCR, such as buffers, enzymes, and primers,
which result in higher cost per sample. MALDI-TOF MS re-
quires only the medium to culture the organism and a small
quantity of matrix (typically, less than 1 g/sample), the cost of
which is negligible in comparison to PCR/ESI-MS, for which
additional costs provide additional capabilities. Overall, both
methods show promise for both routine and, in some cases,
epidemiological use in hospital settings. These two techniques,
in a direct comparison, show no statistically significant differ-
ences in their performance. This report emphasizes the key
differences between the two techniques, both of which will fill
unique niches in the clinical microbiology laboratory.
PCR/ESI-MS
PCR/ESI-MS instruments measure the mass/charge ratio
(m/z) of amplicons, generated by multiplex PCRs that target
several loci within bacterial or fungal genomes. The method
targets both conserved and species-specific genetic regions to
identify microbes based on amplicon base compositions rela-
tive to a known database of microorganisms (16). Using the
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Abbott PLEX-ID or the Ibis T5000 instruments, PCR/ESI-MS
is known for its ability to directly detect and identify bacteria
and associated antibiotic resistance genes, viruses, fungi, and
mycobacteria from clinical specimens and from isolates. Most
recently, the method produced highly accurate results when
used to identify pathogens directly from blood culture bottles
(32). Genetic identification allows for discrimination to the
strain type and allows identification of antimicrobial resistance
genes. Through the use of multiple consensus primers, this
method can detect target gene sequences despite silent muta-
tions or genetic rearrangement, for example, in influenza virus
(43).
PCR/ESI-MS offers extended utility for epidemiological sur-
veillance and infection control. Testing can occur from bacte-
rial isolates or directly from the clinical specimen. PCR/
ESI-MS requires approximately 4 to 6 h for specimen testing.
The method can identify mixtures of up to three to four mi-
crobes but requires the batching of six samples at a time. While
protocols exist, errors in interpretation can occur when com-
binations of staphylococci and streptococci or of staphylococci
and enterococci are found in the same sample (32). In these
situations, one organism is preferentially amplified and iden-
tified. Misidentifications also occur when large differences in
the bacterial densities of microbes are observed for mixed
infections, such that only one of the two organisms is detected.
Errors also occur for mixed infections for which the second
identification is due to an incompletely populated database or
genetically similar organisms belonging to the Enterobacteria-
ceae family. Future additions to the database with isolates from
this family should resolve many of the issues for PCR/ESI-MS
(32).
MALDI-TOF MS
Analysis of whole cells was first proposed in 1975 to study
the biomarker profile of various bacterial species following
pyrolysis-mass spectrometry for low-molecular-weight prod-
ucts (2). However, it was not until 1996 that the first MALDI-
TOF MS experiment was successful in identifying bacteria
directly from whole colonies based on protein biomarkers (10,
26). A great number of developments have been made over the
last decade on whole-organism MALDI-TOF MS. The protein
biomarkers that are measured in mass spectrometry of micro-
organisms are highly expressed proteins responsible for house-
keeping functions, such as ribosomal, chaperone, and tran-
scription/translation factor proteins.
In contrast to PCR/ESI-MS, MALDI-TOF MS relies on
identification of protein profiles derived from highly conserved
proteins and currently identified microbes, bacteria, fungi, and
mycobacteria, to the species level. For MALDI-TOF, the pro-
tein profiles are generated from direct ionization of an intact
colony or a bacterial protein extract after manual extraction.
Identification occurs after a protein’s spectral signature is cor-
related to a database of spectra collected from reference
strains. MALDI-TOF MS, in its current form, requires subcul-
ture prior to identification. An advantage of MALDI-TOF MS
is that it does not require batching.
MALDI-TOF MS is widely used because of its high accu-
racy, low consumable cost, and speed of analysis. A typical
experiment consists of outgrowth of bacteria, colony selection
and placement on a target, addition of matrix, and analysis
with MALDI-TOF MS. Mass spectrometry identification is
broadband such that the method can measure multiple ana-
lytes simultaneously, does not require prior knowledge about
the organism, and is both fast and sensitive in that it does not
require a prefractionation step. It generally measures all m/z
between 2 and 20 kDa. Several reviews are available on this
topic for a more in-depth overview (14, 19, 35).
Commercial systems exist that can integrate with traditional
antimicrobial susceptibility systems. The MALDI Biotyper
(Bruker Daltonics) has proven accuracy in the identification of
bacteria (37), even for rare or fastidious bacteria, which are
often a challenge to clinical laboratories using phenotypic
identification evaluation due to their limited biochemical re-
activity. Identification of yeast has also been reported (38). The
method finds common use in Europe, where clinical microbi-
ologists are using it to rapidly identify microbial colonies iso-
lated from culture. Another MALDI-TOF system, the Vitek
MS (bioMe´rieux), shows similar capabilities to the Bruker sys-
tem. No statistically significant difference was identified be-
tween the two platforms for general bacteria (9).
A few reports show promise for the identification of micro-
organisms using MALDI-TOF MS without subculture (20, 39,
41, 44). Recent evaluations showed promise, but the methods
were limited by the need for a large number of cells; adapta-
tions showed successful identification for only approximately
80% of blood cultures. A promising new technology, the
MALDI Sepsityper system (Bruker Daltonics), is under eval-
uation and aims to identify bacteria and yeast directly from
positive blood culture bottles. If successful, the MALDI Sep-
sityper has the potential to reduce the time-to-identification
for many different species.
It is important to note some of the current limitations asso-
ciated with MALDI-TOF MS. The outgrowth of organisms
from potentially contaminated material is still required in or-
der to obtain isolated colonies of organisms as the technique’s
ability to resolve mixtures is lacking. Additionally, a high num-
ber of bacterial cells are required for identification, such that a
whole intact colony is typically used for analysis, limiting the
ability to rapidly identify microorganisms directly from biolog-
ical fluids where the bacterial count is expected to be relatively
low. Research is currently being done to mitigate some of these
requirements. Finally, until accurate determinations of resis-
tance factors can be made, parallel culture-based recovery of
positive blood cultures will most certainly be required for the
foreseeable future for antimicrobial susceptibility testing.
QUESTIONS DISCUSSED AND RECOMMENDATIONS:
DOES MASS SPECTROMETRY ADD BENEFIT TO
LABORATORIES IN TERMS OF TURNAROUND
TIME AND/OR OUTCOMES?
General recommendations. (i) There is a need for creation
of clinical laboratory consortiums or user groups to combine
data from multisite investigations of new technology to meet
Clinical Laboratory Improvement Act (CLIA) requirements
for laboratory-developed test (LDT) method verification.
These consortiums could share specimens, such as rare blood
culture isolates, and provide feedback to achieve the ultimate
goal of rapid assessment of new technology. Multisite evalua-
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tion networks, sharing a common ground with an organization
such as the American Society for Microbiology (ASM), would
allow users to quickly and easily see deidentified results of
technology assessment across the United States, increasing the
statistical power of any evaluation in terms of accuracy, preci-
sion, turnaround time, etc. While ensuring accurate data is the
critical first step to technology implementation, it is clearly not
the only critical aspect; the cost-benefit model must be fully
justified. Many organizations were verbally reporting require-
ments by administrators for a capital return on investment in 1
to 2 years. This is an almost impossible task for clinical labo-
ratories to achieve without some form of group collaboration
and assessment of recovered costs and overall hospital savings.
The laboratory budget cannot be considered on its own for
some of the new technology platforms; benefits must be doc-
umented at the level of the health care organization itself.
These assessments require organizational collaboration with
finance, pharmacy, and laboratories. Building clinical microbi-
ology networks would enable faster translation of new technol-
ogy as well as much faster assessment of the cost benefit of new
technology. Virtual meeting venues, software to links specimen
biorepositories, encrypted data, and access to biostatisticians
were among the key infrastructure elements identified as ca-
pabilities that the clinical laboratory would need to create
before such a plan could succeed. These networks could be
used as venues for clinical trial participation when an assay
enters the FDA pathway or for assessment of evidence-based
laboratory intervention programs for new technology. Stan-
dardized methods evaluation protocols, in compliance with the
CLIA requirements, and statistically based assessment of new
technology will be imperative for laboratories to create bench-
to-bedside pipelines for rapid evaluations and, if warranted,
adoption of new technology. These consortiums could also
work through ASM to help ensure appropriate reimburse-
ments for testing of multiplex or broad-range technology. Fi-
nally, member laboratories could share business model strate-
gies successfully employed for the purchase of high-cost
technologies in which “fill-in-the-blank” financial formats are
provided.
(ii) Formalized consortiums between the clinical microbiol-
ogy professionals, the infectious disease pharmacy profession-
als, and the medical community to plan the cost benefit, clinical
utility, and antimicrobial stewardship experiments could occur
in conjunction with initial laboratory use. Such collaboration at
the national and local level should enable more accurate and
timely assessment of the impact of new technologies on patient
care and provide financial evaluation of the technology impact.
Recent literature suggests that these collaborations may be
critical to the success of new technologies to drive antibiotic
de-escalation and thus decrease mortality, decrease costs, and
support antimicrobial stewardship (27).
(iii) Culture methods are not obsolete, nor will they be in the
future. Even with the advent of increased molecular-based and
protein-based microbial identification testing, there is an enor-
mous need to continue culture-based testing to assess suscep-
tibility for all antimicrobials and to identify microbes with
mutations that may escape detection by new technology.
(iv) As more-rapid microbiology test methods become stan-
dards of care and as evidence-based studies prove the benefit
of rapid testing and interpretation of microbiology results,
laboratories will need to maintain or expand their clinical prac-
tices to operate around the clock every day of the year, ex-
panding coverage for microbiology testing on all shifts. The
evidence is clear in its support of rapid and targeted antibiotic
administration, a practice that is driven by the speed in which
the laboratory can provide an actionable result. Notification of
positive blood culture bottles and associated pathogen identi-
fication appear to be vital components to drive the de-escala-
tion process; therefore, laboratories must expand collabora-
tions with pharmacists and physicians and strive for rapid
de-escalation of broad-spectrum antibiotics to optimize patient
care and reduce mortality.
(v) Initiatives for publication of diagnostic method evalua-
tion exist, and the working group urges adoption of initiatives,
such as the STARD (standards for reporting of diagnostic
accuracy) program (6). Authors could elect to meet the
STARD criteria for their publication, which would increase its
value and enable easier and more standardized comparison of
publications for meta-analysis, evidence-based review, or gen-
eral use.
(vi) In order for the clinical laboratory to assess the effec-
tiveness of new technology and outcomes related to laboratory
interventions, laboratorians must begin to think and train dif-
ferently, with more emphasis on evidence-based interventions.
There is a critical need to undertake initiatives to manage the
large amounts of bioinformatics data that will soon be created
by multiplex and broad-range technology platforms. Likewise,
there is a critical need to undertake initiatives to manage the
large amounts of medical and financial informatics required to
assess the utility and cost benefit of new technology. Clinical
laboratory science (CLS) programs should consider adding
curricula to introduce medical informatics, bioinformatics,
health care management, and financial management, at least at
the level of master’s degree programs. The American Board of
Medical Microbiology Committee on Postgraduate Education
Programs (CPEP) should offer the same type of curricula at
the doctoral level. Clinical microbiology organizations are
urged to offer certificate programs or continuing medical ed-
ucation (CME) to meet the future workplace needs in med-
ical informatics and bioinformatics. In addition, we urge
laboratory scientists at all levels of the profession to under-
take management course work or degrees such as a master’s
in health administration. Additionally, increased training in
biostatistics is warranted in support of quality improvement
initiatives as well as translational and clinical research ef-
forts. Clinical microbiology organizations are urged to offer
certificate programs or CME to meet the workplace educa-
tional needs for management, financial planning, biostatis-
tics, and bioinformatics.
Recommendations for mass spectrometry instrument ven-
dors and the FDA. (i) We encourage regulatory agencies to
recognize the urgent need for MALDI-TOF and similar rapid
detection technologies for identification of pathogens directly
from blood culture bottles, as well as to identify antimicrobial
resistance and genotyping capabilities. If a fast-track option
were to be considered for evaluation of 510(k) or premarket
authorization (PMA) submissions, clinical microbiologists in
the United States encourage the FDA to consider use as stake-
holders with them in approaching this option. Access to new
technology in Europe and Canada places clinical microbiolo-
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gists in the United States at a professional disadvantage, and
the working group strongly encourages faster availability for
the U.S. market. Vendors should recognize the need for PCR/
ESI-MS platforms that are smaller and less costly in terms of
capital investment and in yearly maintenance costs to enable a
wider user group within clinical laboratories. Further, improve-
ments toward a more random access option for the technology,
or a stat override of the 96-well format, were identified as
desirable.
(ii) From a reimbursement perspective, the working group
agreed that research-use-only (RUO) or laboratory-developed
test (LDT) status will not be acceptable for microbial identi-
fication technologies in the long term. The submission of meth-
ods for expedited FDA review and approval is critical to the
clinical microbiology community. Increased dialogue with the
developers and the clinical microbiology community is war-
ranted, as well as increased dialogue between FDA and the
clinical microbiology professionals, who can advise agency rep-
resentatives about the needs and potential benefits of new
technology. New categories may be warranted, similar to the
emergency use authorization (EUA), not for public health
emergencies but, rather, for use in clinical laboratories to ad-
dress (a) urgent workplace needs for automation and work
flow reduction and (b) assays and technology with the potential
for a high impact and a likelihood to improve medical care.
(iii) For evaluation of molecular- or proteomics-based as-
says, the working group recommended that phenotypic meth-
ods should not be used alone as the reference standard for
comparison. Rather, sequencing methods such as 16S analysis
for discrepancy testing should be included to ensure the high-
est accuracy.
WILL TECHNOLOGY BE AVAILABLE TO ALL OR ONLY
TO LARGE REFERENCE LABORATORIES?
General recommendations. (i) By virtue of cost, complexity,
and throughput, many of the newly developed technologies will
only be affordable for large reference or university-based di-
agnostic laboratories. The working group strongly urges the
development of platforms that could have utility for hospitals,
regardless of their size. (ii) Based on preliminary reports of
accuracy and assuming that the technology can be adapted to
all hospitals, there is a strong possibility that molecular- and
protein-based testing will replace traditional biochemical test-
ing methods and interface with traditional susceptibility test
systems to become the identification methods of choice. (iii)
There is an important need to develop middleware that would
enable users from multiple health care organizations to inter-
face with new technology such as mass spectrometry.
Session discussants: Cara Bastulli, Mathew J. Binnicker, Deborah
Boldt-Houle, Paul Bourbeau, Lynn Boyer, Paul Campognone, Larry
Hambleton, Stephen G. Jenkins, Sue Kehl, Markus Kostrzewa, Mi-
chael Loeffelholz, Linda M. Mann, Elizabeth M. Marlowe, Anne Rob-
inson-Dunn, Paul Schreckenberger, Ribhi Shawar, and Mary Ann Sil-
vius.
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